查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771712

美國阿茲海默症診斷市場規模、佔有率、趨勢分析報告（按診斷技術、類型、最終用途、細分市場預測），2025-2030 年

U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

美國阿茲海默症診斷市場規模預計在2024年達到35.3億美元，2025年至2030年的複合年成長率為10.6%。這一成長主要源於阿茲海默症的疾病上升以及對早期準確診斷的日益重視。根據美國疾病管制與預防中心 (CDC) 的數據，到2024年，美國將有約670萬老年人罹患阿茲海默症，預計到2060年這一數字將增加近一倍。阿茲海默症患者病率的上升促使各國政府和私人醫療機構大力投資PET影像、腦脊髓液生物標記和血液診斷等先進診斷技術。

美國阿茲海默症診斷市場的成長得益於近期先進非侵入性診斷技術的核准。美國食品藥物管理局 (FDA) 已批准首款透過血液檢測輔助診斷阿茲海默症的體外診斷設備上市。 Lumipulse G pTau217/B-澱粉樣蛋白 1-42 血漿比例旨在早期檢測澱粉樣斑塊的形成，這是阿茲海默症病理學的一個標誌，特別適用於 55 歲及以上、出現與認知障礙相符臨床症狀和體徵的成年患者。

這項進展標誌著阿茲海默症診斷領域的重大進步，並透過提供一種經濟高效、微創的PET掃描和脊椎穿刺替代方案，顯著降低了診斷門檻。 FDA強調，此次核准可能使美國患者能夠更早、更輕鬆、更方便地接受檢測。這凸顯了該檢測在促進阿茲海默症早期進展中及時干預和臨床決策方面的價值。

老年人失智症診斷率的上升正在推動美國阿茲海默症診斷市場的成長。根據美國疾病管制與預防中心 (CDC) 2022 年的全國健康訪問調查，約有 4% 的 65 歲及以上人群被診斷患有失智症，而 85 歲及以上人群的這一數字則上升至 13%。這一成長主要得益於預期壽命的延長、認知度的提高以及臨床診斷方法的改善。這推動了對擴充性、準確的診斷解決方案的需求，這些解決方案可支援早期發現、適當的干涉和最佳化的護理計劃。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國阿茲海默症診斷市場變數、趨勢和範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
  • 產業分析工具
    • 波特分析
    • PESTEL分析

第4章美國阿茲海默症診斷市場：診斷技術評估與趨勢分析

  • 美國阿茲海默症診斷市場（按診斷技術）：關鍵要點
  • 2024 年及 2030 年診斷技術趨勢分析及市場佔有率
  • 按診斷技術，2018-2030 年
    • 生物標記
    • 診斷影像技術
    • 基因檢測
    • 認知評估測試

第5章美國阿茲海默症診斷市場：類型估計和趨勢分析

  • 美國阿茲海默症診斷市場（按類型）：關鍵要點
  • 2024 年和 2030 年類型趨勢分析和市場佔有率
  • 按類型，2018-2030
    • 分類
    • 診斷
    • 篩檢

第6章美國阿茲海默症診斷市場：最終用途估計與趨勢分析

  • 美國阿茲海默症診斷市場（按最終用途分類）：關鍵要點
  • 2024 年和 2030 年最終用途變化分析和市場佔有率
  • 按應用，2018-2030 年
    • 醫院
    • 診斷實驗室
    • 學術研究所

第7章 競爭態勢

  • 公司分類
  • 公司市場定位
  • 公司熱圖分析
  • 公司簡介/上市公司
    • GE HealthCare
    • Siemens Healthineers AG
    • Canon Medical Systems Corporation
    • Cerveau Technologies, Inc.
    • Neurovision Imaging, Inc.
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • Quanterix Corporation
    • Alzheon Inc.
    • NanoSomiX, Inc.
    • DiamiR Biosciences
Product Code: GVR-4-68040-628-1

Market Size & Trends:

The U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030. This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics.

The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive impairment.

This development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease progression.

The increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning.

U.S. Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Alzheimer's disease diagnostics market report based on diagnostic technique, type, and end-use:

  • Diagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030)
  • Biomarkers
    • CSF Biomarkers
    • Blood-Based Biomarkers
  • Imaging Diagnostic Techniques
  • Genetic Testing
  • Cognitive Assessment Tests
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Triage
  • Diagnosis
  • Screening
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Diagnostic Laboratories
  • Academic & Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources and Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation and Data Visualization
  • 1.6. Data Validation and Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Alzheimer's Disease Diagnostics Market Variables, Trends and Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Industry Challenge
  • 3.3. Industry Analysis Tools
    • 3.3.1. PORTER's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and social landscape
      • 3.3.2.3. Technological landscape

Chapter 4. U.S. Alzheimer's Disease Diagnostics Market: Diagnostic Technique Estimates and Trend Analysis

  • 4.1. U.S. Alzheimer's Disease Diagnostics Market, By Diagnostic Technique: Key Takeaways
  • 4.2. Diagnostic Technique Movement Analysis and Market Share, 2024 and 2030
  • 4.3. Market Estimates and Forecasts, By Diagnostic Technique, 2018 - 2030 (USD Million)
    • 4.3.1. Biomarkers
      • 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. CSF Biomarkers
        • 4.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Blood-Based Biomarkers
        • 4.3.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Imaging Diagnostic Techniques
      • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Genetic Testing
      • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Cognitive Assessment Tests
      • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Alzheimer's Disease Diagnostics Market: Type Estimates and Trend Analysis

  • 5.1. U.S. Alzheimer's Disease Diagnostics Market, By Type: Key Takeaways
  • 5.2. Type Movement Analysis and Market Share, 2024 and 2030
  • 5.3. Market Estimates and Forecasts, By Type, 2018 - 2030 (USD Million)
    • 5.3.1. Triage
      • 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Diagnosis
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Screening
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Alzheimer's Disease Diagnostics Market: End Use Estimates and Trend Analysis

  • 6.1. U.S. Alzheimer's Disease Diagnostics Market, By End Use: Key Takeaways
  • 6.2. End Use Movement Analysis and Market Share, 2024 and 2030
  • 6.3. Market Estimates and Forecasts, By End Use, 2018 - 2030 (USD Million)
    • 6.3.1. Hospitals
      • 6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Diagnostic Laboratories
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Academic and Research Institutes
      • 6.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Positioning
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles/Listing
    • 7.4.1. GE HealthCare
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Diagnostic Technique Portfolio
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Siemens Healthineers AG
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Diagnostic Technique Portfolio
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Canon Medical Systems Corporation
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Diagnostic Technique Portfolio
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Cerveau Technologies, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Diagnostic Technique Portfolio
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Neurovision Imaging, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Diagnostic Technique Portfolio
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Thermo Fisher Scientific Inc.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Diagnostic Technique Portfolio
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Bio-Rad Laboratories, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Diagnostic Technique Portfolio
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Quanterix Corporation
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Diagnostic Technique Portfolio
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Alzheon Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Diagnostic Technique Portfolio
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. NanoSomiX, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Diagnostic Technique Portfolio
      • 7.4.10.4. Recent Developments/ Strategic Initiatives
    • 7.4.11. DiamiR Biosciences
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Diagnostic Technique Portfolio
      • 7.4.11.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbrevation
  • Table 2 U.S. alzheimer's disease diagnostics market: key market driver analysis
  • Table 3 U.S. alzheimer's disease diagnostics market: Key market restraint analysis
  • Table 4 U.S. alzheimer's disease diagnostics market estimates and forecast, by diagnostic technique (USD Million)
  • Table 5 U.S. alzheimer's disease diagnostics market estimates and forecast, by type (USD Million)
  • Table 6 U.S. alzheimer's disease diagnostics market estimates and forecast, by end use (USD Million)
  • Table 7 Recent developments and impact analysis by key market participants
  • Table 8 Company heat map analysis, 2024
  • Table 9 Companies implementing key strategies

List of Figures

  • Fig. 1 U.S. Alzheimer's disease diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing and forecasting
  • Fig. 7 Parent market analysis
  • Fig. 8 Market formulation and validation
  • Fig. 9 U.S. Alzheimer's disease diagnostics market snapshot
  • Fig. 10 U.S. Alzheimer's disease diagnostics market segment snapshot
  • Fig. 11 U.S. Alzheimer's disease diagnostics market competitive landscape snapshot
  • Fig. 12 Market research process
  • Fig. 13 Market driver relevance analysis (Current and future impact)
  • Fig. 14 Market restraint relevance analysis (Current and future impact)
  • Fig. 15 U.S. Alzheimer's disease diagnostics market: Diagnostic technique outlook key takeaways (USD Million)
  • Fig. 16 U.S. Alzheimer's disease diagnostics market: Diagnostic technique movement analysis 2024 & 2030 (USD Million)
  • Fig. 17 Biomarkers market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Imaging diagnostic Techniques market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Genetic testing market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cognitive assessment tests market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Alzheimer's Disease Diagnostics market: Type outlook key takeaways (USD Million)
  • Fig. 22 U.S. Alzheimer's Disease Diagnostics market: Type movement analysis 2024 & 2030 (USD Million)
  • Fig. 23 Triage market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Diagnosis market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Screening market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. alzheimer's disease diagnostics market: End Use outlook key takeaways (USD Million)
  • Fig. 27 U.S. alzheimer's disease diagnostics market: End Use movement analysis 2024 & 2030 (USD Million)
  • Fig. 28 Hospitals market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic Laboratories market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Academic and Research Institutes market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Strategy framework
  • Fig. 32 Company categorization